Market Overview

CardioNet Says Study Supports Efficacy of MCOTTM for Detection of Atrial Fibrillation in Stroke Patients

Related BEAT
BioTelemetry, Inc. Announces That Eric Prystowsky M.D. Will Transition From the Board Of Directors Into A Medical Advisory Role
BioTelemetry, Inc. Announces Reinstatement Of Cigna Corporation's Coverage Of Mobile Cardiac Monitoring Services

CardioNet, Inc. (NASDAQ: BEAT), the leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, today announced the publication of a new clinical study that further supports CardioNet's Mobile Cardiac Outpatient Telemetry (MCOT^TM) in detecting a high rate of atrial fibrillation in cryptogenic stroke.

This new study, titled “Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke,” was authored by Daniel J Miller, MD, et al, Henry Ford Hospital, Department of Neurology, and was published online on October 24th in the Journal of the Neurological Sciences. The study showed that MCOT^TM frequently detects paroxysmal atrial fibrillation in patients with cryptogenic stroke and transient ischemic attack (TIA). This study is confirmation of the value of MCOT^TM for monitoring patients with cryptogenic stroke and TIA for atrial fibrillation, one potential and treatable, cause of stroke.

Posted-In: News FDA

 

Related Articles (BEAT)

Around the Web, We're Loving...

Get Benzinga's Newsletters